Advertisement

The Role of Small Bioactive Peptides and Cell Surface Peptidases in Androgen Independent Prostate Cancer

  • Joel B. Nelson
Part of the Contemporary Cancer Research book series (CCR)

Abstract

At current rates of diagnosis, a man in the United States has a one-in-five chance that invasive prostate cancer will develop in his lifetime (69).This rate is nearly twice that of lung cancer and three times that of colorectal cancer. Death from prostate cancer is the second leading cause of death from cancer in men in the United States. Almost every man with advanced prostate cancer will undergo androgen ablation therapy and in time, most will progress. The central characteristic of fatal prostate cancer is androgen independence. These facts were established in 1941, when therapeutic castration was first described (53,54), and, unfortunately, still hold true as the 1990s drew to a close. Historically, there has been an inverse relationship between efforts to maximize the efficacy of hormonal therapy for prostate cancer and the outcomes of those efforts: thousands of patients studied and billions of dollars spent repeatedly show hormonal therapy to have dramatic—yet ultimately ineffective—therapeutic effects (67). Although a number of growth and survival factors have been implicated in the androgen independent phenotype of prostate cancer, there has been no translation of these findings to effective therapy (87).

Keywords

Prostate Cancer Human Prostate Cancer Prostate Cancer Cell Line Neutral Endopeptidase Caveolin Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abrahamsson, P. 1996. Neuroendocrine differentiation and hormone refractory prostate cancer. Prostate (Suppl.)6: 3–8.Google Scholar
  2. 2.
    Alam A. S. M. T., A. Gallagher, V. Shankar, et al. 1992. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology 130: 3617–3624.PubMedCrossRefGoogle Scholar
  3. 3.
    Almenoff, J. and M. Orlowski. 1983. Membrane-bound kidney neutral metalloendopeptidase: interaction with synthetic substrates, natural peptides, and inhibitors. Biochemistry 22: 590–598.PubMedCrossRefGoogle Scholar
  4. 4.
    Anastasi, A., V. Erspamer, and M. Bucci. 1971. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of European amphibians Bombyna and Alytes. Experimentia 27: 166–167.CrossRefGoogle Scholar
  5. 5.
    Angelsen, A., U. Syversen, M. Stridsberg, et al. 1997. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 31: 110–117.PubMedCrossRefGoogle Scholar
  6. 6.
    Antequera, F., B. Boyes, and A. P. Bird. 1990. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62: 503–514.PubMedCrossRefGoogle Scholar
  7. 7.
    Aprikian, A. G., K. Han, S. Chevalier, et al. 1996. Bombesin specfically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J. Mol. Endocrinol. 16: 297–306.PubMedCrossRefGoogle Scholar
  8. 8.
    Aprikian, A. G., L. Tremblay, K. Han, et al. 1997. Bombesin stimulates the motility of human prostate carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins. Int. J. Cancer 72: 498–504.PubMedCrossRefGoogle Scholar
  9. 9.
    Aprikain, A. G., K. Han, L. Guy, et al. 1998. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate (Suppl.)8: 52–61.Google Scholar
  10. 10.
    Aria, H., K. Nakao, K. Takaya, et al. 1993. The human endothelin-B receptor gene: structural organization and chromosomal assignment. J. Biol. Chem. 268: 3463–3470.Google Scholar
  11. 11.
    Bartholdi, M. F., J. M. Wu, H. Pu, et al. 1998. In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int. J. Cancer 79: 82–90.Google Scholar
  12. 12.
    Battey, J. F., J. M. Way, M. J. Corjay, et al. 1991. Molecular cloning of the bombesin/ gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc. Natl. Acad. Sci. USA 88: 395–399.PubMedCrossRefGoogle Scholar
  13. 13.
    Battistini, B., P. Chailler, P. D’Orleans-Juste, et al. 1993. Growth regulatory properties of endothelins. Peptides 14: 385–399.PubMedCrossRefGoogle Scholar
  14. 14.
    Baylin, S. B., M. Makos, J. J. Wu, et al. 1991. Abnormal pattern of DNA methylation in human neoplasia: potential consequences for tumor progression. Cancer Cells 3: 383–390.PubMedGoogle Scholar
  15. 15.
    Blackburn, A. M., D. R. Fletcher, and S. R. Bloom. 1980. Effect of neurotensin on gastric function in man. Lancet 1: 987–989.PubMedCrossRefGoogle Scholar
  16. 16.
    Bologna, M., C. Festuccia, P. Muzi, et al. 1989. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63: 1714–1720.Google Scholar
  17. 17.
    Bunn, P. A., D. G. Dienhart, D. Chan, et al. 1990. Neuropeptide stimulation of calcium flux in human lung cancer cells: delineation of alternative pathways. Proc. Natl. Acad. Sci. USA 87: 2162–2166.PubMedCrossRefGoogle Scholar
  18. 18.
    Carney, D. N., F. Cutitta, T. W. Moody, et al. 1987. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-realeasing peptide. Cancer Res. 47: 821–825.PubMedGoogle Scholar
  19. 19.
    Carraway, R. and S. E. Leeman. 1973. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalamus. J. Biol. Chem. 248: 6854–6861.PubMedGoogle Scholar
  20. 20.
    Carraway, R., and S. E. Leeman. 1976. Characterization of radioimmunoassayable neurotensin in the rat: its differential distribution in the central nervous system, small intestine and stomach. J. Biol. Chem. 251: 7045–7052.PubMedGoogle Scholar
  21. 21.
    Carraway, R. E., S. P. Mitra, and D. E. Cochrane. 1987. Structure of a biologically active neurotensin-related peptide obtained from pepsin treated albumins. J. Biol. Chem. 262: 5968–5973.PubMedGoogle Scholar
  22. 22.
    Casey, M. L., W. Byrd, and P. C. MacDonald. 1992. Massive amounts of immunoreactive endothelin in human seminal fluid. J. Clin. Endocrinol. Metabol. 74: 223–225.CrossRefGoogle Scholar
  23. 23.
    Chun, M., U. K. Liyanage, M. P. Lisanti, et al. 1994. Signal transduction of a G protein-coupled receptor in caveolae: colocalization of endothelin and its receptor with caveolin. Proc. Natl. Acad. Sci. USA 91: 11, 728–11, 732.Google Scholar
  24. 24.
    Chun, M., H. Y. Lin, Y. I. Henis, et al. 1995. Endothelin-induced endocytosis of cell surface ETA receptors: endothelin remains intact and bound to the ETA receptor. J. Biol. Chem. 270: 10,855–10, 560.Google Scholar
  25. 25.
    Corjay, M. H., D. J. Dobrzanski, J. M. Way, et al. 1991. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J. Biol. Chem. 266: 18,771–18, 779.Google Scholar
  26. 26.
    Cussenot, O., J. M. Villette, A. Valeri, et al. 1996. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J. Urol. 155: 1340–1343.PubMedCrossRefGoogle Scholar
  27. 27.
    Cutitta, F., D. N. Carney, J. Mulshine, et al. 1985. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 316: 823–826.CrossRefGoogle Scholar
  28. 28.
    Cyr, C., K. Huebner, T. Druck, et al. 1991. Cloning and chromosomal localization of a human endothelin ETA receptor. Biochem. Biophys. Res. Commun. 181: 184–190.PubMedCrossRefGoogle Scholar
  29. 29.
    Dahlof, B., D. Gustafsson, T. Hedner, et al. 1990. Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reactions. J. Hypertens. 8: 811–817.PubMedCrossRefGoogle Scholar
  30. 30.
    Daub, H., F. U. Weiss, C. Wallasch, et al. 1996. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379: 557–560.PubMedCrossRefGoogle Scholar
  31. 31.
    Davar, G., G. Hans, M. U. Fareed, et al. 1998. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 13: 2279–2283.CrossRefGoogle Scholar
  32. 32.
    Davis, T. P., H. S. Burgess, S. Crowell, et al. 1989.13-endorphin and neurotensin stimulate in vitro clonal growth of human SCLC cells. Eur. J. Pharmacol. 161: 283–285.Google Scholar
  33. 33.
    Deftos, L., S. Nakada, D. Burton, et al. 1996. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 48: 58–62.PubMedCrossRefGoogle Scholar
  34. 34.
    Deftos, L. J. and P. Abrahamsson. 1998. Granins and prostate cancer. Urology 51: 141–145.PubMedCrossRefGoogle Scholar
  35. 35.
    De-Melo, J. D., C. R. Tonussi, P. D’Orleans-Juste, et al. 1998. Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists. Pain 77: 261–269.PubMedCrossRefGoogle Scholar
  36. 36.
    di Sant’Agnese, P. A. 1998. Neuroendocrine differentiation in prostatic carcinoma: an update. Prostate 8S: 74–79.PubMedGoogle Scholar
  37. 37.
    Economos, K., P. C. Macdonald, and M. L. Casey. 1992. Endothelin-1 gene expression and biosynthesis in human endometrial HEC-1A cancer cells. Cancer Res. 52: 554–557.PubMedGoogle Scholar
  38. 38.
    Erdös, E. G., W. W. Schulz, J. T. Gafford, et al. 1985. Neutral metalloendopeptidase in human male genital tract: comparison to angiotensin I-converting enzyme. Lab. Invest. 52: 437–447.PubMedGoogle Scholar
  39. 39.
    Erspamer, V., G. F. Erspamer, M. Inselvini, et al. 1972. Occurrence of bombesin and alytesin in extracts of the skin of three European discoglossid frogs and pharmacological actions of bombesin on extravascular smooth muscle. Br. J. Pharmacol. 45: 333–3348.PubMedCrossRefGoogle Scholar
  40. 40.
    Festuccia, C., F. Guerra, S. D’Ascenzo, et al. 1998. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int. J. Cancer 75: 41 8–431.Google Scholar
  41. 41.
    Feurle, G. E., B. Muller, and E. Rix. 1987. Neurotensin induces hyperplasia of the pancreas and growth of the gastric antrum in rats. Gut (Suppl.)28: 19–23.Google Scholar
  42. 42.
    Fletcher, D. R., A. M. Blackburn, T. E. Adrian, et al. 1981. Effect of neurotensin on pancreatic function in man. Life Sci. 29: 2157–2161.PubMedCrossRefGoogle Scholar
  43. 43.
    Fukahiro, T., T. Fujikawa, S. Ozaki, et al. 1994. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem. Biophys. Res. Commun. 199: 1461–1465.CrossRefGoogle Scholar
  44. 44.
    Gafford, J. T., R. A. Skidgel, E. G. Erdös, et al. 1983. Human kidney “enkephalinase,” a neutral metaloendopeptidase that cleaves active peptides. Biochemistry 22: 3265–3275.PubMedCrossRefGoogle Scholar
  45. 45.
    Galetti, T. P., G. P. Rossi, A. Belloni, et al. 1996. Localization of endothelin receptors A and B in normal human prostate and BPH. J. Urol. 155: 463A.Google Scholar
  46. 46.
    Ghatei, M. A., R. T. Jung, J. C. Stevenson, et al. 1982. Bombesin action on gut hormones and calcium in man. J. Clin. Endocrinol. Metab. 54: 980–985.PubMedCrossRefGoogle Scholar
  47. 47.
    Gu, J., M. Polak, L. Probert, et al. 1983. Peptidergic innervation of the human male genital tract. J. Urol. 130: 386–391.PubMedGoogle Scholar
  48. 48.
    Han, K., J. Viallet, S. Chevalier, et al. 1997. Characterization of intracellular calcium mobilization by bombesin-related neuropeptides in PC-3 human prostate cancer cells. Prostate 31: 53–60.PubMedCrossRefGoogle Scholar
  49. 49.
    Heikkila, R., J. B. Trepel, F. Cuttitta, et al. 1987. Bombesin-related peptides induce calcium mobilization in a subset of human small cell lung cancer cell lines. J. Biol. Chem. 262: 16,456–16, 460.Google Scholar
  50. 50.
    Hoosein, N. M., C. J. Logothetis, and L. W. K. Chung. 1993. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J. Urol. 149: 1209.PubMedGoogle Scholar
  51. 51.
    Hoosein, N., M. Abdul, R. McCabe, et al. 1995. Clinical significance of elevation of neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol. Oncol. 1: 246–254.PubMedCrossRefGoogle Scholar
  52. 52.
    Hsu, J.-Y. and M. Pfahl. 1998. ET-1 expression and growth inhibition of prostate cancer cells: a retoid target with novel specificity. Cancer Res. 58: 4817–4822.PubMedGoogle Scholar
  53. 53.
    Huggins, C. and C. V. Hodges. 1941. Studies on prostatic cancer: I. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1: 293–303.Google Scholar
  54. 54.
    Huggins, C., R. E. Stevens, and C. V. Hodges. 1941. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43: 209–223.CrossRefGoogle Scholar
  55. 55.
    Huggins, S. P., J. T. Pelton, and R. C. Miller. 1993. The structure and specificity of endothelin receptors: their importance in physiology and medicine. Pharmacol. Ther. 59: 55–123.PubMedCrossRefGoogle Scholar
  56. 56.
    Inoue, A., M. Yanagisawa, S. Kimura, et al. 1989. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA 86: 2863–2867.PubMedCrossRefGoogle Scholar
  57. 57.
    Ishizuka, J., C. M. Townsend, J. C. Thompson, et al. 1993. Neurotensin regulates growth of human pancreatic cancer. Ann. Surg. 217: 439–446.PubMedCrossRefGoogle Scholar
  58. 58.
    Jones, P. A. 1996. DNA methylation errors and cancer. Cancer Res. 56: 2463–2467.PubMedGoogle Scholar
  59. 59.
    Jungwirth, A., J. Pinski, G. Galvan, et al. 1997. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinizing hormone releasing hormone antagonist cetrolix and bombesin antagonists RC-3940-II and RC-3950-II. Eur. J. Cancer 33: 1141–1148.PubMedCrossRefGoogle Scholar
  60. 60.
    Kapuscinski, M., A. Shulkes, D. Read, et al. 1990. Expression of neurotensin in endocrine tumors. J. Clin. Endocrinol. Metab. 70: 100–106.PubMedCrossRefGoogle Scholar
  61. 61.
    Kitabgi, P., F.Checler, J. Maxella, et al. 1985. Pharmacology and biochemistry of neurotensin receptors. Rev. Clin. Basic Pharm. 5: 397–486.PubMedGoogle Scholar
  62. 62.
    Kobayashi, S., R. Tang, B. Wang, et al. 1994. Binding and functional properties of endothelin receptor subtypes in the human prostate. Mol. Pharmacol. 45: 306–311.PubMedGoogle Scholar
  63. 63.
    Kobayashi, S, R. Tang, B. Wang, et al. 1994. Localization of endothelin receptors in the human prostate. J. Urol. 151: 763–766.PubMedGoogle Scholar
  64. 64.
    Kochva, E., C. C. Viljoen, and D. P. Botes. 1982. A new type of toxin in the venom of snakes of the genus Atractaspis (Atractaspidinae). Toxicon 20: 581–592.PubMedCrossRefGoogle Scholar
  65. 65.
    Kochva, E., A. Bdolah, and Z. Wollberg. 1993. Sarafotoxins and endothelins: evolution, structure and function. Toxicon 31: 541–568.PubMedCrossRefGoogle Scholar
  66. 66.
    Kondo, S., T. Morita, and Y. Tashima. 1994. Endothelin receptor density in human hypertrophie and non-hypertrophic prostate tissue. Tohoku J. Exp. Med. 172: 381–384.PubMedCrossRefGoogle Scholar
  67. 67.
    Kozlowski, J. M., and J. T. Grayhack. 1991. Carcinoma of the prostate, in Adult and Pediatric Urology ( Gillenwater, J. Y., J. T. Grayhack, S. S. Howards, and J. W. Duckett, eds.), Mosby-Year Book, St. Louis, MO, pp. 1277–1393.Google Scholar
  68. 68.
    Kusuhara, M., K. Yamaguchi, K. Nagasaki, et al. 1990. Production of endothelin in human cancer cell lines. Cancer Res. 50: 3257–3261.PubMedGoogle Scholar
  69. 69.
    Landis, S. H., T. Murray, S. Bolden, et al. 1998. Cancer Statistics, 1998. CA Cancer J. Clin. 48: 6–29.PubMedCrossRefGoogle Scholar
  70. 70.
    Langenstroer, P., R. Tang, E. Shapiro, et al. 1993. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J. Urol. 149: 495–499.Google Scholar
  71. 71.
    Lebacg-Verheyden, A. M., J. Trepel, E. A. Sausville, et al. 1990. Peptide growth factors and their receptors. Handbook Exp. Pharmacol. 95: 71–124.CrossRefGoogle Scholar
  72. 72.
    Le Brun, G., F. Moldovan, P. Aubin, et al. 1996. Identification of endothelin receptors in normal and hyperplastic human prostate tissues. Prostate 28: 379–384.PubMedCrossRefGoogle Scholar
  73. 73.
    Lee, W.-H., R. A. Morton, J. I. Epstein, et al. 1994. Cytidine methylation of regulatory sequences near the it-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91: 11,733–11, 737.Google Scholar
  74. 74.
    Lisanti, M. P., P. E. Schere, J. Vidugiriene, et al. 1994. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J. Cell Biol. 126: 111–126.PubMedCrossRefGoogle Scholar
  75. 75.
    McDonald, T. J., H. Jornvall, G. Hilsson, et al. 1979. Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem. Biophys. Res. Commun. 90: 227–233.PubMedCrossRefGoogle Scholar
  76. 76.
    Milovanovic, S. R., S. Radulovic, K. Groot, et al. 1992. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160. Prostate 20: 269–280.PubMedCrossRefGoogle Scholar
  77. 77.
    Mogard, M. H., R. Kobayashi, C. F. Chen, et al. 1986. The amino acid sequence of kinetensin, a novel peptide isolated from pepsin-treated human placenta: homology with human serum albumin, neurotensin and angiotensin. Biochem. Biophys. Res. Commun. 136: 983–988.PubMedCrossRefGoogle Scholar
  78. 78.
    Moody, T. W., C. A. Mayr, T. J. Gillespie, et al. 1998. Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines. Peptides 19: 253–258.PubMedCrossRefGoogle Scholar
  79. 79.
    Nagy, A., P. Armatis, R.-Z. Cai, et al. 1997. Dosing, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. USA 94: 652–656.PubMedCrossRefGoogle Scholar
  80. 80.
    Nakamuta, M., R. Takayanagi., Y. Sakai, et al. 1991. Cloning and sequence analysis of a cDNA encoding human non-selective type of endothelin receptor. Biochem. Biophys. Res. Commun. 177: 34–39.PubMedCrossRefGoogle Scholar
  81. 81.
    Narayan, S., E. R. Spindel, N. H. Rubin, et al. 1992. A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects. Cell Growth Differ. 3: 111–118.PubMedGoogle Scholar
  82. 82.
    Nasu, Y., T. L. Timme, G. Yang, et al. 1998. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen insensitive mouse prostate cancer cells. Nat. Med. 4: 1062–1064.PubMedCrossRefGoogle Scholar
  83. 83.
    Nelson, J., M. Donnelly, B. Walker, et al. 1991. Bombesin stimulates proliferation of human breast cancer cells in culture. Br. J. Cancer 63: 933–936.PubMedCrossRefGoogle Scholar
  84. 84.
    Nelson, J. B., S. P. Hedican, D. J. George, et al. 1995. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1: 944–949.PubMedCrossRefGoogle Scholar
  85. 85.
    Nelson, J. B., K. Chan-Tack, S. P. Hedican, et al. 1996. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 56: 663–668.PubMedGoogle Scholar
  86. 86.
    Nelson, J. B., W.-H. Lee, S. H. Nguyen, et al. 1997. Methylation of the 5’ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 57: 35–37.PubMedGoogle Scholar
  87. 87.
    Nelson, J. B. 1998. Alternatives to death: understanding androgen independent prostate cancer. Nat. Med. 4: 1011–1012.PubMedCrossRefGoogle Scholar
  88. 88.
    Nelson, J. B., S. H. Nguyen, J. R. Wu-Wong, et al. 1999. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53: 1063–1069.PubMedCrossRefGoogle Scholar
  89. 89.
    Nelson, J. B. and M. A. Carducci. 2000. Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer. Cancer Investigation. 18: 87–96.PubMedCrossRefGoogle Scholar
  90. 90.
    Papandreou, C. N., B. Usmani, Y. Geng, et al. 1998. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat. Med. 4: 50–57.PubMedCrossRefGoogle Scholar
  91. 91.
    Pflug, B. R., R. Reiter, and J. B. Nelson. 1999. Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 40: 269–273.PubMedCrossRefGoogle Scholar
  92. 92.
    Pinski, J., G. Halmos, K. Szepeshazi, et al. 1993. Antagonists of bombesin/gastrinreleasing peptide as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Cancer 72: 3263–3270.PubMedCrossRefGoogle Scholar
  93. 93.
    Pinski, J., H. Reile, G. Halmos, et al. 1994. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res. 54: 169–174.PubMedGoogle Scholar
  94. 94.
    Reddi, A. H., and C. Huggins. 1972. Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc. Natl. Acad. Sci. USA 69: 1601–1605.PubMedCrossRefGoogle Scholar
  95. 95.
    Reddi, A. H. and N. E. Sullivan. 1980. Matrix-induced endochondral bone differentiation influence of hypophysectomy, growth hormone, and thyroid-stimulating hormone. Endocrinology 107: 1291–1299.PubMedCrossRefGoogle Scholar
  96. 96.
    Reile, H., P. E. Armatis, and A. V. Schally. 1994. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate 25: 29–38.PubMedCrossRefGoogle Scholar
  97. 97.
    Rubanyi, G. M., and M. A. Polokoff. 1994. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46: 325–415.PubMedGoogle Scholar
  98. 98.
    Schrey, M. P., K. V. Patel, and N. Tezapsidis. 1992. Bombesin and glucocorticoids stimulate human breast cancer cells to produce endothelin, a paracrine mitogen for breast stromal cells. Cancer Res. 52: 1786–1790.PubMedGoogle Scholar
  99. 99.
    Seethalakshmi, L., S. P. Mitra, P. R. Dobner, et al. 1997. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 31: 183–192.PubMedCrossRefGoogle Scholar
  100. 100.
    Sehgal, I., S. Powers, B. Huntley, et al. 1994. Neurotensin is an autocrine trophic growth factor stimulated by androgen withdrawal in human prostate cancer. Proc. Natl. Acad. Sci. USA 91: 4673–4677.PubMedCrossRefGoogle Scholar
  101. 101.
    Severi, C., R. T. Jensen, V. Erspamer, et al. 1991. Different receptors mediate the action of bombesin-related peptides on gastric smooth muscle cells. Am. J. Physiol. 260: G683 - G690.PubMedGoogle Scholar
  102. 102.
    Shipp, M. A., J. Vijayaraghavan, E. V. Schmidt, et al. 1989. Common acute lymphoblastic leukemia antigen (Calla) is active neutral endopeptidase 24.11 (“enkephalinase”): direct evidence by cDNA transfection analysis. Proc. Natl. Acad. Sci. USA 86: 297–301.PubMedCrossRefGoogle Scholar
  103. 103.
    Shioide, M. and M. Noda. 1993. Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells. J. Cell Biochem. 53: 176–180.PubMedCrossRefGoogle Scholar
  104. 104.
    Sim, S., A. Glassman, J. Ro, et al. 1996. Serum calcitonin in small cell carcinoma of the prostate. Ann. Clin. Lab. Sci. 26: 487–495.PubMedGoogle Scholar
  105. 105.
    Spindel, E. R., E. Giladi, P. Brehm, et al. 1990. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol. Endocrinol. 4: 1956–1963.PubMedCrossRefGoogle Scholar
  106. 106.
    Suzuki, N., H. Matsumoto, C. Kitada, et al. 1989. Production of endothelin-1 and bigendothelin-1 by tumor cells with epithelial-like morphology. J. Biochem. 106: 736–741.PubMedGoogle Scholar
  107. 107.
    Takasaki, C., M. Yanagisawa, S. Kimura, et al. 1988. Similarity of endothelin to snake venom toxin. Nature 335: 303.CrossRefGoogle Scholar
  108. 108.
    Takuwa, Y., Y. Ohue, N. Takuwa, et al. 1989. Endothelin-1 activates phospholipase C and mobilizes Cat+ from extra-and intracellular pools in osteoblastic cells. Am. J. Physiol. 257: E797–803.PubMedGoogle Scholar
  109. 109.
    Takuwa, Y., T. Masaki, and K. Yamashita. 1990. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem. Biophys. Res. Conmmun. 170: 998–1005.CrossRefGoogle Scholar
  110. 110.
    Walden, P. D., M. Ittmann, M. E. Monaco, et al. 1998. Endothelin-1 production and agonist activites in cultured prostate-derived cells: implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia. Prostate 34: 241.PubMedCrossRefGoogle Scholar
  111. 111.
    Wasilenko, W. J., J. Cooper, A. J. Palad, et al. 1997. Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. Prostate 30: 167–173.PubMedCrossRefGoogle Scholar
  112. 112.
    Webb, M. L., C.-C. Chao, M. Rizzo, et al. 1995. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction. Mol. Pharmacol. 47: 730–737.PubMedGoogle Scholar
  113. 113.
    Weber, H. C., L. L. Hampton, R. T. Jensin, et al. 1998. Structure and chromosomal localization of the mouse bombesin receptor subtype 3 gene. Gene 211: 125–131.PubMedCrossRefGoogle Scholar
  114. 114.
    Weber, S., J. E. Zuckerman, D. G. Bostwich, et al. 1985. Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. J. Clin. Invest. 75: 306–309.CrossRefGoogle Scholar
  115. 115.
    Wood, J. G., H. D. Hoang, L. J. Bussjaeger, et al. 1988. Neurotensin stimulates growth of small intestine in rats. Am. J. Physiol. 255: 813–817.Google Scholar
  116. 116.
    Yamashita, J., M. Ogawa, H. Egami, et al. 1992. Abundant expression of immunoreactive endothelin-1 in mammary phyllodes tumor: possible role of endothelin 1 in the growth of stromal cells in phyllodes tumor. Cancer Res. 52: 4046–4049.PubMedGoogle Scholar
  117. 117.
    Yamashita, J., M. Ogawa, K. Nomura, et al. 1993. Interleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells. Cancer Res. 53: 464–467.PubMedGoogle Scholar
  118. 118.
    Yanagisawa, M., H. Kurihara, S. Kimura, et al. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411–415.PubMedCrossRefGoogle Scholar
  119. 119.
    Yang, G., L. D. Truong, T. L. Timme, et al. 1998. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 8: 1873–1880.Google Scholar
  120. 120.
    Yohn, J. J., C. Smith, T. Stevens, et al. 1994. Autoregulation of endothelin-1 secretion by cultured human keratinocytes via the endothelin B receptor. Biochim. Biophys. Acta 1224: 454–458.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Joel B. Nelson

There are no affiliations available

Personalised recommendations